N/A N=1,918 FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza · Acute Respiratory Infection · Influenza-like Illness
Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=165 Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
Plasma Cell Neoplasm
Primary: Seroprotection Based on Hemagglutination Antibody Inhibition (HAI) — 32; 22 Participants
Phase 4 N=29,255 Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
Influenza
Primary: MAARI Rate During the Epidemic Period (2007-2008) — 12503; 18998 Number of MAARI
N/A N=544 Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
Influenza
Primary: Influenza Vaccine Coverage (Percent) for New Mothers of Newborns — 70; 64 Percentage of Participants
N/A N=87,665 From Innovation to Solutions: Childhood Influenza Vaccination Planning
Influenza
Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05
N/A N=30,537 TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations
Influenza
Primary: Influenza Immunization: Pediatric — 43.6; 39.9 % participant vaccinated with influenza
Phase 3 N=7,250 Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Influenza
Primary: Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains…
N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
Phase 2 N=59 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Influenza
Primary: Mean Area Under the Viral Load-Time Curve (VL-AUC) After Influenza Viral Challenge — 16.09; 10.70 log[10] copies/milliliter (mL)*hour — p=0.0390
Phase 4 N=292 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home
Influenza
Primary: Number of Participants Who Received Influenza Vaccine. — 250 participants
Phase 4 N=125 Development of Childhood Anti-Influenza Immunity
Influenza · Influenza Immunisation
Primary: Frequency of CD4 T Cells With a Given Functional Potential — 0.70; 0.55; 0.52; 0.38 Percentage
Phase 3 N=64 Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Influenza
Primary: Number of Laboratory Confirmed Influenza Infections — 2; 1 infections — p=0.25
Phase 3 N=3,670 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
N/A N=178 Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
Influenza Virus Infection Transmission in Humans
Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number
N/A N=4,455 Study to Evaluate Impact of School-based Influenza Vaccination on School Populations
Influenza
Primary: Rates of Confirmed Influenza Illness in Vaccinated and Non-vaccinated Children Attending Schools With and Without School-based Influenza Vaccination Programs — 58.0…
N/A N=80,452 High-risk Influenza Vaccine Alert
Influenza
Primary: Flu Vaccination — 4459; 4456; 4575 Participants — p=0.517
N/A N=133 Influenza Immunity in Children
Influenza
Primary: Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects — .010; 0.003; 0.009; 0.002 percentage of T cells — p=0.005
Phase 4 N=1,952 Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4
Influenza
Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants
Phase 2 N=79 Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants
Phase 1 N=45 Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
Influenza
Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs
N/A N=558 Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Influenza, Human
Primary: Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs at Day 3 -- Team Collected Samples — 99; 131 Participants…
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 1 N=95 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally
Influenza
Primary: Antibody Responses in Nasal Secretions to Influenza A/H1N1 and A/H3N2 at 14 Days After Intranasal Immunization. — 3; 3; 5; 0 Participants
Phase 4 N=2,957 High Dose Influenza Vaccine in Nursing Home - Pilot Study
Influenza
Primary: Total All-cause Hospitalizations — 197; 301 events
Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season
Influenza
Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…
Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Phase 2 N=200 Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
Upper Respiratory Tract Infections
Primary: Frequency of Influenza-like Illness — 54; 62; 16; 28 participants — p=0.25
N/A N=216 Improving Communication During a Pandemic Flu Outbreak
Healthy
Primary: Change in Intentions to Take Antivirals for Pandemic Flu — 8.29; 8.16; 8.23; 8.35 score on a scale — p=>.05
Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Influenza
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants
Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants